Top 10 Synthetic Biology Companies 2023

Synthetic Biology Companies

1. Amyris Inc.

Market Position or History

• On November 30th, 2011, Total and Amyris, Inc. signed an agreement to expand their R&D partnership and to create joint ventures to develop, manufacture and commercialize a range of renewable fuels and products.
• In 2017 DSM expanded its Strategic Alliance with Amyris and acquired Brazilian Production Facility from Amyris.
• In 2019 Amyris, Inc. launched PURECANE Brand Sweetener on its new website for customers.
• In June 2020, Amyris partnered with AB Mauri North America, this company helps to reduce sugar in baking products using PURECANE sweetener.

Business Overview and Strategy

Amyris Inc. was founded in 2003 and headquartered in Emeryville, California, U.S. It is an industrial biotechnology company. The company is engaged in the engineering, production, and sales of a wide range of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The company manufactures renewable products which focus on fuels and chemicals that provide compromised sustainable options for a wide range of petroleum-sour products. The company’s platform is used to create, fabricate, optimize, and upscale strains on commercial volumes for more than 15 commercial components.

Amyris Inc.'s goal is to provide the right quality of products to the customers. It offers wide product portfolio such as cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, fuels, and other synthetic biology products. The company keeps focusing on objectives to deliver quality products to customers around the world with integrity and ethical business. It is committed to keep people at the center by helping Billions of people around the world with increasing access to quality products, building a strong global presence, and increasing technologies.

2. Thermo Fisher Scientific

Market Position or History

• Thermo Fisher Scientific was created in 2006 by the merger of Thermo Electron and Fisher Scientific. Thermo Fisher has offices and operations in many countries, notably the U.S. and in Europe.
• In 2013, the company acquired Life Technologies Corporation and Advanced Scientific in 2015.
• In 2017, the company acquired Finesse Solutions, Inc., developer of scalable control automation systems and software for bioproduction and
• In 2020, Thermo Fisher opened its new Lenexa facility aimed at boosting the production and manufacturing of COVID-19 testing supplies.
• In 2021, Thermo Fisher acquired Belgium-based viral vector manufacturer.

Business Overview and Strategy

Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company was founded in 1956 and is headquartered in Waltham, Massachusetts, U.S. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Thermo Fisher Scientific Inc. provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. Company has invested $1 billion in2018 to develop high-impact new products. It focuses that significant investment by leveraging the expertise of company's more than 5,000 scientists and engineers, by gaining insights from our world class Scientific Advisory Board and by closely collaborating with its customers. This is how company creates the most impact and generate the highest returns.

3. DuPont de Nemours, Inc.

Market Position or History

• On December 11th, 2015, E. Do Pont de Nemers & Co., commonly known as "DuPont", announced a merger into Do Chemical Company in an all-stock transaction.
• In February 2018, Do DuPont’s Department of Agriculture was renamed Corteva Grisines, its Department of Literary Science was named Doe and its Special Products Department was named Dupoint.
• In February 2020, DuPont announced that it had replaced Edward D., less than a year after taking on the role of former CEO Mark Doyle and CFO Jean-Marie Desmond.

Business Overview and Strategy

It was formerly DowDuPont Inc., provides technology-based materials, ingredients, and solutions. The company has subsidiaries in about 70 countries worldwide and manufacturing operations in about 40 countries. The company operates through five business segment: electronics & imaging, nutrition & bioscience, transportation & industrial, safety & construction and non-core.

DuPont is one of the world’s leading chemical companies and having a strong geographic presence across the world. Furthermore, the company spend huge amount in research and development to innovate the new product, but this activity adds the cost of the product. Hence, company uses pricing strategy to meet customer needs so that the product will be rightly priced and attract more customer. For example, in B2B business the pricing depend on several factors like taxation policies, FDI policies, economic scenario and many others.

4. New England Biolabs Inc.

Market Position or History

• The company was founded in 1974 by Donald Combe as a collaborative laboratory of experienced scientists, and initially developed commercially restricted enzymes.
• The research received about 1.7 billion in small business innovation research (SBIR) grants between 2009 and 2013.
• In 2015, NEB committed to establish a GMP manufacturing facility near its headquarters in Ipswich, Massachusetts, U.S. and the 40,000-sq-ft facility was completed in 2018.

Business Overview and Strategy

New England Biolabs Inc. is a privately held company and has extensive worldwide distribution through a network of exclusive distributors, agents. It is engaged in the discovery and development of restored and original enzymes for genomic research. It has seven subsidiaries located in China, France, Canada, Japan, Singapore, Germany, and the UK. And other regions also.

New England Biolab is committed to collaborate with the scientific research community around the world, as well as its industrial customers on the technology platform, by supplying high-quality reagents, backed by unparalleled production and customer support. To better serve the needs of customers in regulated markets, the company has opened a state-of-the-art 43,000 sq. ft. production facility available in Rowley, MA is about 15 minutes from the main campus in Ipswich, the USA for the production of GSP-grade materials. The Company also concentrates to make more investments in research and development for platform extensions and innovative new products, geographic expansion through acquisition and new product market programs to drive further revenue and profit growth.

5. Genscript

Market Position or History

• In 2002, GenScript was founded in New Jersey, USA.
• In 2004, GenScript established a research and production center in Nanjing, China.
• In 2013, it launched Bestzyme (biotech industrial synthetic biology) product segment. And in 2014, launched the Legend Biotech cell therapy segment.
• In 2015, GenScript Biotech Corporation was listed in HKEK (Stock code: 1548).
• In 2017, the China Food and Drug Administration (CFDA) legend accepted the IND application. Collaboration on the BCMA program was established between Legend and Janssen.

Business Overview and Strategy

Genscript Biotech Corporation is a global biotech company. GenScript was founded in 2002 and headquartered in New Jersey, U.S. by Dr. Fangliang (Frank) Zhang and was listed on the Hong Kong Stock Exchange in 2015. There are more than 100 countries and territories in the genescript business worldwide that exist legally in the U.S., China, Hong Kong, China, Japan, Singapore, the Netherlands, and Ireland.

GenScript aims to be a major leader in global genetics and cell therapy over the next five years, maintaining its leadership and commitment to its core business of gene synthesis technology. The company’s cell therapy department is focused on turning the BCMA program to the professionalism of R / R MM patients in the last line and clinical trials in the front-line MM treatment. The next-generation cell therapy pipeline will target malignant hematological tumors, solid tumors, and infectious diseases using autologous and all-login CAR-T technology. This technology will create new growth potential for Legend Biotech and help the business become the world’s dominating Biopharmaceutical Company.

6. Integrated DNA Technologies Inc.

Business Overview and Strategy

Integrated DNA Technologies Inc. was founded in 1987 and is headquartered in Coralville, IA, U.S. The company develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development. Company serves more than 130,000 life sciences researchers in more than 100 countries and produces more than 90,000 nucleic acids daily. The company has a team of more than 14,000 professionals located in more than 100 countries

The Company is focusing on life sciences research for more than 30 years and develops and manufactures nucleic acid products that support the life sciences industry. Company serves more than 130,000 life sciences researchers in more than 100 countries and produce more than 90,000 nucleic acids daily. The company has team of 14000 professionals located in more than 100 countries which mainly focuses on nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development.

7. Novozymes

Market Position or History

• In 1925, the Harald and Thorvald Pedersen brother founded Novo Terapeutisk Labaratorium and Nordisk Insulin laboratorium to produce insulin.
• In 2000, Novozymes was founded as a spinout from pharmaceutical company Novo Nordisk.
• In 2001, the company acquired Sybron and also contracted with U.S. government to develop enzymes which can turn biomass into environmentally-friendly fuel.
• In 2006, it acquired GroPep and Delta and Philom Bios in 2007.
• In 2014, Novozymes launched Medley, innovative detergent blends that target specific regional needs and conditions.
• In 2020, the company acquired Microbiome Labs.

Business Overview and Strategy

Novozymes was founded in 2000 and is headquartered in Bagsvaerd, Denmark. It is one of the leading in bio innovation companies and producing a wide range of industrial enzymes and microorganism and biopharmaceutical ingredients. It is mainly engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients.

The major strategies points are differentiate to Succeed, thus the company focuses to invest in the right resources, innovation, commercial support or product optimization, to deliver value to its customers, while at the same time reinvesting a significant share of its profit to develop new impactful biological solutions. The company also engaged in the activities to explore the market globally. For example; the company acquired Microbiome Labs to strengthen its position in North American probiotics market.

8. Koninklijke DSM N.V.

Market Position or History

• The DSM was set up by the Dutch state in 1902 to mine coal reserves at southern Limburg, and in 1973, the company had diversified into commodity chemicals and petrochemicals, but DSM maintained its initial link when the last mine closed to this day.
• In 1989, the government sold 70% of the company's shares on the Amsterdam Stock Exchange.
• In 2000, DSM had completed the acquisition with Catalytica Pharmaceuticals.
• In 2005, Royal DSM completed the acquisition with Catalytica Pharmaceuticals; a water-based coating resins company.
• In 2020, The DSM completed an acquisition with Erber Group.

Business Overview and Strategy

The Royal DSM is a science-based company engaged in the business of nutrition, health, and sustainable living in the Netherlands, the rest of Europe, North America, Latin America, China, India, Japan, the rest of Asia, and internationally. DSM is focused on product quality and customer requirements for its growth. It also collectively embraces the concept of sustainability. The company is focused on acquisition strategy for its growth. For example, on November 18^th, 2019; Royal DSM reached agreement with the shareholders of specialty dairy solutions provider Koninklijke CSK Food Enrichment C.V. for the acquisition of a 100% interest in the company for a cash consideration of about €150 Billion.

Furthermore, Royal DSM is committed to keep people at the center by helping Billions of people in South Africa with increasing quality of ingredients, building a strong global presence, and increasing product value in the market. Additionally, the company continue to focus on inventory and redundancy plans to address potential shortfalls for the baking ingredients.

9. Precigen, Inc.

Market Position or History

Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Precigen’s mission is to discover, develop and commercialize next generation gene and cell therapies focused in immuno-oncology, autoimmune disorders, and infectious diseases. The Company is focused on product innovation and partnership activities to be competitive in the market. For example; on November 16^th, 2020; it announced clinical implementation of its UltraPorator system, a device exclusive to Precigen for the scale-up of rapid and cost-effective decentralized manufacturing of UltraCAR-T therapies.

10. Synthetic Genomics Inc.

Market Position or History

• Synthetic Genomics Inc. was founded in 2005 and is headquartered in California, U.S. The company is focused on synthetic biology. It designs and builds biological systems to address global sustainability problems.
• In 2010, Synthetic Genomics spun off a new subsidiary, Synthetic Genomics Vaccines Inc., to develop next generation vaccines.

Business Overview and Strategy

Synthetic Genomics, Inc. (SGI) is a private biotechnology company harnessing the power of algae to make renewable, low carbon and energy dense liquid fuels for heavy duty transportation applications. The Company develops biological solutions for fuel, advanced plant feedstocks, microbial agents for agriculture, and metabolic pathways for production of biochemical.

Synthetic Genomics is a fast-growing company building diverse, talented teams. Company is focused on research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. It also concentrates to invest in the right resources, innovation, commercial support or product optimization, to deliver value to its customers, while at the same time reinvesting a significant share of its profit to develop new impactful biological solutions.